Pfizer's Revenue
- Pfizer's annual revenue was $63.63 B in fiscal year 2024. The annual revenue increased $4.07 B from $59.55 B (in 2023) to $63.63 B (in 2024), representing a 6.84% year-over-year growth.
- Pfizer's quarterly revenue was $16.65 B in the quarter ending Sep 2025. The quarterly revenue decreased -$1.05 B from $17.70 B (in Q3: June 2024) to $16.65 B (in Q3: June 2025), representing a -5.92% year-over-year decline.
- The highest annual revenue for Pfizer was $100.33 B in fiscal year 2022.
- The lowest annual revenue was $41.17 B in fiscal year 2019.
- The average revenue was $60.74 B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2016 - 2025):
Learn more about Pfizer's Revenue by Segment and Revenue by Region.
Check out competitors to Pfizer in a side-by-side comparison.
Explore additional financial metrics for Pfizer.
Definition of Revenue :
Pfizer's Revenue Trend
| 2015 | 48851000000.00 |
|---|---|
| 2016 | 52824000000.00 |
| 2017 | 52546000000.00 |
| 2018 | 53647000000.00 |
| 2019 | 41172000000.00 |
| 2020 | 41651000000.00 |
| 2021 | 81288000000.00 |
| 2022 | 100330000000.00 |
| 2023 | 59553000000.00 |
| 2024 | 63627000000.00 |
| Apr 2016 | 13005000000.00 |
|---|---|
| Jul 2016 | 13147000000.00 |
| Oct 2016 | 13045000000.00 |
| Dec 2016 | 13627000000.00 |
| Apr 2017 | 12779000000.00 |
| Jul 2017 | 12896000000.00 |
| Oct 2017 | 13168000000.00 |
| Dec 2017 | 13703000000.00 |
| Apr 2018 | 12906000000.00 |
| Jul 2018 | 13466000000.00 |
| Sep 2018 | 13298000000.00 |
| Dec 2018 | 13976000000.00 |
| Mar 2019 | 13118000000.00 |
| Jun 2019 | 13264000000.00 |
| Sep 2019 | 12680000000.00 |
| Dec 2019 | 12688000000.00 |
| Mar 2020 | 10083000000.00 |
| Jun 2020 | 9864000000.00 |
| Sep 2020 | 10277000000.00 |
| Dec 2020 | 11634000000.00 |
| Apr 2021 | 14516000000.00 |
| Jul 2021 | 18899000000.00 |
| Oct 2021 | 24035000000.00 |
| Dec 2021 | 23838000000.00 |
| Apr 2022 | 25661000000.00 |
| Jul 2022 | 27742000000.00 |
| Oct 2022 | 22638000000.00 |
| Dec 2022 | 24290000000.00 |
| Apr 2023 | 18486000000.00 |
| Jul 2023 | 13007000000.00 |
| Oct 2023 | 13491000000.00 |
| Dec 2023 | 14570000000.00 |
| Mar 2024 | 14879000000.00 |
| Jun 2024 | 13283000000.00 |
| Sep 2024 | 17702000000.00 |
| Dec 2024 | 17763000000.00 |
| Mar 2025 | 13715000000.00 |
| Jun 2025 | 14653000000.00 |
| Sep 2025 | 16654000000.00 |
2024
Pfizer's annual revenue was $63.63 B in fiscal year 2024.
Pfizer's quarterly revenue was $14.88 B(Q1: Mar 2024), $13.28 B(Q2: Jun 2024), $17.70 B(Q3: Sep 2024), $17.76 B(Q4: Dec 2024) in fiscal year 2024.
2023
Pfizer's annual revenue was $59.55 B in fiscal year 2023.
Pfizer's quarterly revenue was $18.49 B(Q1: Apr 2023), $13.01 B(Q2: Jul 2023), $13.49 B(Q3: Oct 2023), $14.57 B(Q4: Dec 2023) in fiscal year 2023.
2022
Pfizer's annual revenue was $100.33 B in fiscal year 2022.
Pfizer's quarterly revenue was $25.66 B(Q1: Apr 2022), $27.74 B(Q2: Jul 2022), $22.64 B(Q3: Oct 2022), $24.29 B(Q4: Dec 2022) in fiscal year 2022.
2021
Pfizer's annual revenue was $81.29 B in fiscal year 2021.
Pfizer's quarterly revenue was $14.52 B(Q1: Apr 2021), $18.90 B(Q2: Jul 2021), $24.04 B(Q3: Oct 2021), $23.84 B(Q4: Dec 2021) in fiscal year 2021.
2020
Pfizer's annual revenue was $41.65 B in fiscal year 2020.
Pfizer's quarterly revenue was $10.08 B(Q1: Mar 2020), $9.86 B(Q2: Jun 2020), $10.28 B(Q3: Sep 2020), $11.63 B(Q4: Dec 2020) in fiscal year 2020.
2019
Pfizer's annual revenue was $41.17 B in fiscal year 2019.
Pfizer's quarterly revenue was $13.12 B(Q1: Mar 2019), $13.26 B(Q2: Jun 2019), $12.68 B(Q3: Sep 2019), $12.69 B(Q4: Dec 2019) in fiscal year 2019.
2018
Pfizer's annual revenue was $53.65 B in fiscal year 2018.
Pfizer's quarterly revenue was $12.91 B(Q1: Apr 2018), $13.47 B(Q2: Jul 2018), $13.30 B(Q3: Sep 2018), $13.98 B(Q4: Dec 2018) in fiscal year 2018.
2017
Pfizer's annual revenue was $52.55 B in fiscal year 2017.
Pfizer's quarterly revenue was $12.78 B(Q1: Apr 2017), $12.90 B(Q2: Jul 2017), $13.17 B(Q3: Oct 2017), $13.70 B(Q4: Dec 2017) in fiscal year 2017.
2016
Pfizer's annual revenue was $52.82 B in fiscal year 2016.
Pfizer's quarterly revenue was $13.01 B(Q1: Apr 2016), $13.15 B(Q2: Jul 2016), $13.05 B(Q3: Oct 2016), $13.63 B(Q4: Dec 2016) in fiscal year 2016.
Pfizer's Revenue (Year-over-Year Change)
| 2015 | 0 |
|---|---|
| 2016 | +8.13 |
| 2017 | -0.53 |
| 2018 | +2.10 |
| 2019 | -23.25 |
| 2020 | +1.16 |
| 2021 | +95.16 |
| 2022 | +23.43 |
| 2023 | -40.64 |
| 2024 | +6.84 |
| Q1: Apr 16 | 19.71 |
|---|---|
| Q2: Jul 16 | 10.92 |
| Q3: Oct 16 | 7.93 |
| Q4: Dec 16 | -2.99 |
| Q1: Apr 17 | -1.74 |
| Q2: Jul 17 | -1.91 |
| Q3: Oct 17 | 0.94 |
| Q4: Dec 17 | 0.56 |
| Q1: Apr 18 | 0.99 |
| Q2: Jul 18 | 4.42 |
| Q3: Sep 18 | 0.99 |
| Q4: Dec 18 | 1.99 |
| Q1: Mar 19 | 1.64 |
| Q2: Jun 19 | -1.50 |
| Q3: Sep 19 | -4.65 |
| Q4: Dec 19 | -9.22 |
| Q1: Mar 20 | -23.14 |
| Q2: Jun 20 | -25.63 |
| Q3: Sep 20 | -18.95 |
| Q4: Dec 20 | -8.31 |
| Q1: Apr 21 | 43.97 |
| Q2: Jul 21 | 91.60 |
| Q3: Oct 21 | 133.87 |
| Q4: Dec 21 | 104.90 |
| Q1: Apr 22 | 76.78 |
| Q2: Jul 22 | 46.79 |
| Q3: Oct 22 | -5.81 |
| Q4: Dec 22 | 1.90 |
| Q1: Apr 23 | -27.96 |
| Q2: Jul 23 | -53.11 |
| Q3: Oct 23 | -40.41 |
| Q4: Dec 23 | -40.02 |
| Q1: Mar 24 | -19.51 |
| Q2: Jun 24 | 2.12 |
| Q3: Sep 24 | 31.21 |
| Q4: Dec 24 | 21.91 |
| Q1: Mar 25 | -7.82 |
| Q2: Jun 25 | 10.31 |
| Q3: Sep 25 | -5.92 |
2024
Pfizer’s annual revenue increased +6.84% during fiscal year 2024 compared to 2023. It represents a growth of $4.07 B from $59.55 B (in 2023) to $63.63 B (in 2024).
2023
Pfizer’s annual revenue decreased -40.64% during fiscal year 2023 compared to 2022. It represents a decline of -$40.78 B from $100.33 B (in 2022) to $59.55 B (in 2023).
2022
Pfizer’s annual revenue increased +23.43% during fiscal year 2022 compared to 2021. It represents a growth of $19.04 B from $81.29 B (in 2021) to $100.33 B (in 2022).
2021
Pfizer’s annual revenue increased +95.16% during fiscal year 2021 compared to 2020. It represents a growth of $39.64 B from $41.65 B (in 2020) to $81.29 B (in 2021).
2020
Pfizer’s annual revenue increased +1.16% during fiscal year 2020 compared to 2019. It represents a growth of $479.00 M from $41.17 B (in 2019) to $41.65 B (in 2020).
2019
Pfizer’s annual revenue decreased -23.25% during fiscal year 2019 compared to 2018. It represents a decline of -$12.48 B from $53.65 B (in 2018) to $41.17 B (in 2019).
2018
Pfizer’s annual revenue increased +2.10% during fiscal year 2018 compared to 2017. It represents a growth of $1.10 B from $52.55 B (in 2017) to $53.65 B (in 2018).
2017
Pfizer’s annual revenue decreased -0.53% during fiscal year 2017 compared to 2016. It represents a decline of -$278.00 M from $52.82 B (in 2016) to $52.55 B (in 2017).
2016
Pfizer’s annual revenue increased +8.13% during fiscal year 2016 compared to 2015. It represents a growth of $3.97 B from $48.85 B (in 2015) to $52.82 B (in 2016).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2024 | $63.63 B | +6.84% |
| 2023 | $59.55 B | -40.64% |
| 2022 | $100.33 B | +23.43% |
| 2021 | $81.29 B | +95.16% |
| 2020 | $41.65 B | +1.16% |
| 2019 | $41.17 B | -23.25% |
| 2018 | $53.65 B | +2.10% |
| 2017 | $52.55 B | -0.53% |
| 2016 | $52.82 B | +8.13% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q3: Sep 25 | $16.65 B | -5.92% |
| Q2: Jun 25 | $14.65 B | 10.31% |
| Q1: Mar 25 | $13.72 B | -7.82% |
| Q4: Dec 24 | $17.76 B | 21.91% |
| Q3: Sep 24 | $17.70 B | 31.21% |
| Q2: Jun 24 | $13.28 B | 2.12% |
| Q1: Mar 24 | $14.88 B | -19.51% |
| Q4: Dec 23 | $14.57 B | -40.02% |
| Q3: Oct 23 | $13.49 B | -40.41% |
| Q2: Jul 23 | $13.01 B | -53.11% |
| Q1: Apr 23 | $18.49 B | -27.96% |
| Q4: Dec 22 | $24.29 B | 1.90% |
| Q3: Oct 22 | $22.64 B | -5.81% |
| Q2: Jul 22 | $27.74 B | 46.79% |
| Q1: Apr 22 | $25.66 B | 76.78% |
| Q4: Dec 21 | $23.84 B | 104.90% |
| Q3: Oct 21 | $24.04 B | 133.87% |
| Q2: Jul 21 | $18.90 B | 91.60% |
| Q1: Apr 21 | $14.52 B | 43.97% |
| Q4: Dec 20 | $11.63 B | -8.31% |
| Q3: Sep 20 | $10.28 B | -18.95% |
| Q2: Jun 20 | $9.86 B | -25.63% |
| Q1: Mar 20 | $10.08 B | -23.14% |
| Q4: Dec 19 | $12.69 B | -9.22% |
| Q3: Sep 19 | $12.68 B | -4.65% |
| Q2: Jun 19 | $13.26 B | -1.50% |
| Q1: Mar 19 | $13.12 B | 1.64% |
| Q4: Dec 18 | $13.98 B | 1.99% |
| Q3: Sep 18 | $13.30 B | 0.99% |
| Q2: Jul 18 | $13.47 B | 4.42% |
| Q1: Apr 18 | $12.91 B | 0.99% |
| Q4: Dec 17 | $13.70 B | 0.56% |
| Q3: Oct 17 | $13.17 B | 0.94% |
| Q2: Jul 17 | $12.90 B | -1.91% |
| Q1: Apr 17 | $12.78 B | -1.74% |
| Q4: Dec 16 | $13.63 B | -2.99% |
| Q3: Oct 16 | $13.05 B | 7.93% |
| Q2: Jul 16 | $13.15 B | 10.92% |
| Q1: Apr 16 | $13.01 B | 19.71% |
